INTRODUCTION
Cystic fibrosis (CF) is a genetic disorder that leads to chronic multisystem disease consisting of chronic sinopulmonary infections, malabsorption, and nutritional abnormalities. It is the most common autosomal recessive life-shortening disease among Caucasians in the United States. Although multiple organ systems are affected in this disease, lung involvement is the major cause of morbidity and mortality. From a pulmonary perspective, a cycle of chronic, persistent infections with CF-related pathogens and an excessive inflammatory response progressively damage the airways and lung parenchyma, resulting in widespread bronchiectasis and, ultimately, early death from respiratory failure [1, 2] .
CF is caused by mutations in a gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cyclic adenosine monophosphate-regulated ion channel. CFTR functions primarily as a chloride and bicarbonate channel and controls the movement of fluid into and out of epithelial cells lining the respiratory tract, biliary tree, intestines, vas deferens, sweat ducts, and pancreatic ducts. The discovery of the gene responsible for CF 25 years ago [3] has enabled an understanding of how various mutations lead to specific alterations in the structure and function of the CFTR protein. Over 1900 CFTR mutations and variants have been identified, although over 80% of people with CF in the United States possess at least one copy of the most common mutation, F508del [4] . This knowledge eventually led to the discovery and development of compounds that modulate CFTR function, thus targeting the basic defect in CF. Development of CFTR-targeted therapies represents a new era in CF treatment, one that is revolutionizing the care of CF patients.
ERA OF PRECISION MEDICINE IN CYSTIC FIBROSIS
In 2015, the second CFTR protein modulator therapy, ivacaftor/lumacaftor (Orkambi, Vertex Pharmaceuticals, Boston, USA), was approved by the United States Food and Drug Administration (FDA) for individuals with CF ages 12 years and older with two copies of the F508del mutation, thus providing a potential treatment for approximately 50% of people with CF who are homozygous for F508del. The first, ivacaftor (Kalydeco, Vertex Pharmaceuticals, Boston, USA), has been available in the United States since 2012 as a stand-alone therapy for CF individuals with the G551D and other gating mutations. Now, more than 10 000 people living with CF can benefit from drugs that treat the underlying genetic cause of their disease.
The development and targeted use of ivacaftor and lumacaftor are great examples of how the CF community is at the forefront of the field of precision medicine. Precision medicine essentially means tailoring treatments based on an individual's genetic makeup. President Barack Obama highlighted the pioneering advances in CF treatments in his 2015 State of the Union address and in a speech launching the Precision Medicine Initiative (https:// www.nih.gov/precision-medicine-initiative-cohortprogram).
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MUTATION CLASSES
Over 1900 mutations or variants in the CFTR gene have been identified, although not all are disease causing. CFTR mutations can be broadly categorized into five classes based on the effect of the mutation on the protein (Fig. 1) [1,5 & ,6,7] . Class I mutations result in altered RNA processing and absent or truncated CFTR protein as a result of nonsense, splice site or frameshift mutations. Class II mutations, which include F508del, lead to folding or maturation defects and thus, little detectable CFTR in the cell membrane. Class III mutations, typified by the G551D mutation, are gating mutations that result in CFTR protein that reaches the cell membrane but is nonfunctional secondary to gating defects that limit channel opening. Class IV and V mutations are associated with either reduced chloride conductance through the CFTR channel or reduced levels of the CFTR protein at the cell membrane, respectively. The most commonly detected class IV mutation is the R117H which has an additional layer of clinical phenotype variability based on polymorphisms in the poly-T tract in intron 8 of the CFTR gene [8] . Individuals with the R117H mutation with a 7T tract are generally expected to do well, with low risk of disease progression and sweat chloride values in the intermediate to normal range, while those with a 5T tract are at higher risk of developing lung disease and may have sweat chloride values in the CF diagnostic range.
Classes I-III mutations result in minimal protein function; thus, people with two copies of these mutations typically have the classic CF phenotype including pancreatic insufficiency. Individuals with at least one Class IV or V mutation (i.e. partial function mutations) typically have residual CFTR function and sufficient pancreatic function to absorb nutrients without supplemental pancreatic enzymes (i.e. pancreatic sufficiency), and may have sweat chloride values in the CF diagnostic or intermediate ranges [9] . Although classifying mutations into distinct classes provides a useful framework, in reality many mutations including F508del result in problems with CFTR protein production and function at multiple steps, adding to the complexity of achieving fully restored CFTR activity. In addition to CFTR genotype, modifier genes and environmental factors influence the variability of CF phenotype and co-morbidities and may contribute to differences in treatment response [10] [11] [12] .
KEY POINTS
CFTR mutations result in different functional protein consequences, ranging from complete protein absence to defective protein activity at the cell surface.
CFTR modulators have been successfully developed and are now approved for use in CF.
Potentiators increase the gating or opening of the mutant CFTR channel on the cell surface whereas correctors stabilize and chaperone the misfolded CFTR protein to the cell surface.
In-vitro preclinical testing of CFTR modulator drugs in airway and intestinal epithelial cells from individuals with CF is being investigated to determine whether this can further personalize the approach to treatment.
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CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATION

Potentiators
The first CFTR modulator to gain approval for clinical use by the United States FDA was ivacaftor (Kalydeco), a CFTR 'potentiator' that works by opening the dysfunctional CFTR channel present at the cell surface ( Fig. 1 ). Potentiators work on CFTR protein that has reached the cell membrane; thus, individuals with class III gating mutations and class IV conductance defects are the most likely to benefit from stand-alone potentiator therapy. Two pivotal phase III clinical trials of ivacaftor demonstrated rapid, dramatic, and sustained improvements in lung function [forced expiratory volume in 1 s (FEV 1 )], weight, quality of life, and biomarkers of CFTR function (sweat chloride), as well as reductions in pulmonary exacerbations in people with at least one copy of the G551D gating mutation [13, 14] . As a result, in 2012, the FDA approved ivacaftor for CF patients ages 6 years and older with the G551D mutation. A 96-week, open-label extension study of ivacaftor confirmed findings from the initial phase III studies and showed persistence of benefits in lung function, weight, and quality of life over 3 years [15 && ]. Based on further studies in individuals with other non-G551D class III gating mutations and in young children, ivacaftor has now been approved for those with eight additional gating mutations (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) [16 && ] and for children as young as 2 years of age (ClinicalTrials.gov Identifier: NCT01705145). Although gating mutations such as the G551D are present in only about 5% of the United States CF population, the dramatic success of ivacaftor proved that rescue of mutant CFTR was possible, paving the way for the development and clinical testing of additional CFTR modulators that target the majority of patients with CF.
Ivacaftor is now approved for use in individuals with the class IV conductance mutation, R117H. A 24-week, randomized, double-blind, placebocontrolled trial of ivacaftor in people ages 6 years and older with the R117H mutation (7T or 5T poly-T tracts) demonstrated decreased sweat chloride, and in patients 18 years of age and older, improved lung function and quality of life [17 && ]. Participants ages 6-17 (n ¼ 19) did not experience statistically significant improvements in lung function or quality of life. However, the number of pediatric subjects enrolled was small, and children with the R117H mutation typically have mild disease phenotypes making detection of clinically significant changes more difficult. Phase IV postapproval studies are on-going which will provide additional information about which patients with the R117H may benefit the most from treatment with ivacaftor. Additionally, a pilot study was recently completed testing the benefit of ivacaftor in CF subjects 12 years and older with phenotypic or molecular evidence of residual CFTR function (ClinicalTrials.gov Identifier: NCT01685801). This study was a randomized, double-blind, placebo-controlled, multiple-within-participant crossover design (N-of-1 trial), used to study subjects with rare CFTR mutations associated with residual function [18 & ]. This study design is a unique model, in which each patient served as their own control, using precision medicine to study rare genetic mutations in a rare disease.
Correctors
In 2015, the first combination corrector/potentiator treatment, lumacaftor/ ivacaftor (Orkambi), was approved for use in patients homozygous for the F508del mutation, ages 12 years and older. CFTR 'correctors' work by increasing trafficking of the CFTR protein to the cell membrane (Fig. 1 ). The F508del mutation (a class II mutation with defective trafficking) has been the target of intense research due to its high prevalence within the CF community. Restoring CFTR function in those with the F508del mutation appears to require a combination approach with a corrector to increase the amount of protein at the cell surface along with a potentiator to increase gating of the abnormal CFTR channel. The potentiator, ivacaftor, had been previously studied as monotherapy in patients with the F508del mutation and found to have no substantial effect on CFTR function or clinical outcomes [19] . FDA approval was based on one phase II trial [20 & ] and two phase III randomized, double-blind, placebo-controlled studies of lumacaftor/ivacaftor (n ¼ 1108 subjects) which demonstrated modest but sustained improvements in lung function and decreased rates of pulmonary exacerbations over 24 weeks, along with a good safety profile [21 && ]. Although the approval of a CFTR modulator for the almost 50% of individuals with CF who are homozygous for the F508del mutation was an enormous step forward in the treatment of CF, the clinical gains are modest, and second generation correctors are already in clinical trials with the hope of restoring more CFTR function [22 & ,23].
READ-THROUGH AGENTS
The CFTR modulator program also includes treatment strategies directed towards suppression of premature termination codons (class I mutations) present in approximately 10% of United States CF patients (Fig. 1) . 
GENE THERAPY AND GENE EDITING
Gene therapy has been under investigation since the CF gene was discovered in 1989. Various vectors have been tested for DNA-based gene delivery in CF, including recombinant adenoviral and adeno-associated viral vectors as well as nonviral, synthetic (e.g. plasmid) vectors [29 & ]. The goal of gene therapy is to use a vector to effectively deliver functional CFTR DNA to the nucleus of lung epithelial cells, such that functional CFTR protein can be transcribed in place of the mutated CFTR gene. The largest phase I/IIa safety and phase IIb multidose gene therapy clinical trials were published in 2015, testing a plasmid-based, nonviral gene therapy vector in CF subjects in the United Kingdom [30 && ,31 & ] . In this randomized, double-blind, placebo-controlled study, subjects received monthly doses of plasmid-based gene therapy via nebulization for 12 months. At the end of treatment, subjects receiving gene therapy showed stabilization of lung function compared to a decline seen in the placebo group. Overall, treated subjects had a 3.7% improvement in FEV 1 compared with placebo. There were no significant toxicities with treatment.
The development of RNA-based recombinant lentivirus vectors and emerging gene editing technology (e.g. CRISPR/Cas9) have the promise to make the repair of the mutated CFTR gene a future possibility [32] [33] [34] . Although these systems have not yet been studied clinically in CF, they offer the ultimate opportunity for precision medicine, correcting the specific CFTR mutation in the patient. 
TOWARD PERSONALIZED THERAPIES IN CYSTIC FIBROSIS
While ivacaftor and lumacaftor have proven efficacious in large clinical trials, variable clinical responses were observed in these trials, underscoring the need to screen drugs on an individual level. Researchers are developing model systems, derived from biopsies of airway and intestinal epithelial cells and blood samples from individuals with CF, and recent breakthroughs in stem cell biology now allow for expansion and storage of these cells [35 & ]. In-vitro preclinical testing of CFTR modulator drugs can then be performed to select the most effective drugs or combinations for that particular individual (i.e. personalized medicine). The use of primary human airway epithelial cells grown in culture has been exploited successfully in the development of CFTR modulators. For example, the analysis of primary human airway epithelial monolayers derived from a G551D/F508del donor provided the preclinical data to justify the evaluation of ivacaftor in human subjects, despite the absence of efficacy data in an animal model [36] . Because access to bronchial epithelial cells is limited, nasal airway epithelial cells are also being examined as a model system for CFTR therapeutics. Primary nasal epithelial cells share many phenotypic features with human bronchial epithelial cells [37, 38] . Intestinal organoids or 'enteroids' grown from stem cells obtained from intestinal biopsy tissue serve as another model system to test CFTR modulators, as activation of CFTR leads to organoid swelling [39] . In addition, circulating monocytes and macrophages are being studied to determine whether these readily available circulating immune cells are a valuable source of cells to investigate CFTR modulators. Being able to screen drug efficacy at the individual level using airway or intestinal cells or blood samples acquired from patients with CF will facilitate personalized medicine in CF.
CONCLUSION
The recent development of CFTR modulators promises to transform the therapeutic landscape in CF in a precision based fashion. FDA approvals of the CFTR modulators ivacaftor and lumacaftor/ ivacaftor combination therapy demonstrate the effectiveness of potentiators and correctors in people with specific CF genotypes. Ongoing improvements in modulator therapy, as well as advancements in gene therapy and gene editing systems, are paving the way for therapies targeting the basic defect in all people with CF. Model systems of airway and intestinal epithelial cells from individuals with CF to test CFTR modulators represent just how customized care could become once a broader range of CFTR drugs become available.
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